Abeona Therapeutics (ABEO) Cash & Current Investments (2010 - 2026)

Abeona Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $168.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 99.95% year-over-year to $168.3 million; the TTM figure through Mar 2026 stood at $168.3 million (up 99.95% YoY), while the FY2025 annual figure was $191.4 million, up 95.19% from the prior year.
• Cash & Current Investments was $168.3 million for Q1 2026 at Abeona Therapeutics, down from $191.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $225.9 million in Q2 2025 to a low of $18.2 million in Q3 2022.
• Historically, Cash & Current Investments has averaged $93.5 million across 5 years, with a median of $62.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments slumped 73.27% in 2022, then jumped 231.57% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $52.5 million in 2022, then rose by 0.15% to $52.6 million in 2023, then jumped by 86.55% to $98.1 million in 2024, then soared by 95.19% to $191.4 million in 2025, then decreased by 12.09% to $168.3 million in 2026.
• The last three Cash & Current Investments figures came in at $168.3 million (Q1 2026), $191.4 million (Q4 2025), and $207.5 million (Q3 2025), per Business Quant data.